Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001645 · ClinicalTrials.gov registry record

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

A clinical trial of Malaria and Intestinal Worms, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
800
Enrollment target
1
Study location

NCT00001645: Recruiting study of Malaria and Intestinal Worms, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00001645 is a study of Malaria and Intestinal Worms that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 800 participants, above the 229-participant average among 27 other Malaria trials with a reported enrollment target (249% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001645, a study of Malaria and Intestinal Worms, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
800 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at least 1 year old may be enrolled. This study does not involve any experimental treatments. Participants will have a physical examination and laboratory tests on blood, stool, or urine. Blood samples may be collected at regular intervals, but no more than 450 ml (15 ounces) of blood will be drawn from adults, and no more than 7 ml (1-1/2 teaspoons) per kg (2.2 pounds) of body weight from children, in any 6-week period. Other tests may include x-rays, electrocardiogram (EKG), or tissue biopsy (surgical removal of a small tissue sample), depending on the individual s condition. Patients may be offered treatment or may be referred to another study that is more appropriate for the problem. Any treatment provided in this study will be according to standard medical practice for the patient s specific medical problem. Patients responses to treatment will be evaluated at regularly scheduled clinic visits. The length of time between visits and the total duration of the study for a given individual will be determined by the study doctor, based on that person s medical condition.

Primary Outcome

Elimination of parasitic infection.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 1998-10-10

What NCT00001645 shows while recruiting

NCT00001645 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 229-participant average among 27 other Malaria trials with a reported enrollment target (249% higher).

The record links to 5 conditions, with Malaria appearing as the primary indexed condition, and to 0 interventions.

NCT00001645 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00001645 about?

NCT00001645 is a clinical study titled "Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection". The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at least 1 year old may be enrolled. This study does not involve any experimental treatments. Participants will have a physical examination an...

What is the current status of trial NCT00001645?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 1998-10-10.

What conditions does trial NCT00001645 study?

This clinical trial studies the following conditions: Malaria, Intestinal Worms, GI Protozoa, Echiniococcus, Strongyloides.

Who is sponsoring clinical trial NCT00001645?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001645 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001645's enrollment target sits among peer trials

800 3rd of 27 higher than 25 of 27 other Malaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00001645, the US trial registry maintained by the National Library of Medicine. NCT00001645 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.